Trump administration readies new tariffs on select drugmakers: Report

The Trump administration is set to announce tariffs as soon as Thursday on drugmakers that have not struck deals guaranteeing low ‌prices in ⁠the ⁠U.S., Bloomberg News reported on Wednesday, citing people familiar with the plan.

The White House did not immediately respond to Reuters' request for comment.

The Trump administration has been considering a 100% ⁠tariff on imported ‌branded and patented medicines, prompting global drugmakers to ramp up ⁠U.S. manufacturing and stockpile inventory.


Also read: Trump expected to overhaul steel and aluminum tariffs, WSJ reports

Pfizer and AstraZeneca have secured multi-year tariff exemptions through pricing deals and commitments to the new TrumpRx.gov platform. Eli Lilly, Johnson & Johnson and Merck have pledged billions to expand U.S. operations to ‌avoid penalties.

Companies that do not have agreements and are not in negotiations with the ⁠administration will be subject to 100% tariffs, the report said.

The plans are not final and could still change, and there could also be exemptions for some medicines and disease categories, it said.